Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG₁ antibody

References

• Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021;20(7):491–14. doi:10.1038/d41573-021-00079-7.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. MAbs. 2023;15(1):2153410. doi:10.1080/19420862.2022.2153410.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell. 2022;185(15):2789–805. doi:10.1016/j.cell.2022.05.029.
   PubMed Web of Science ®Google Scholar
• Viola M, Sequeira J, Seica R, Veiga F, Serra J, Santos AC, Ribeiro AJ. Subcutaneous delivery of monoclonal antibodies: How do we get there? J Control Release. 2018;286:301–314. doi:10.1016/j.jconrel.2018.08.001.
   PubMed Web of Science ®Google Scholar
• Pitiot A, Heuze-Vourc’h N, Secher T. Alternative Routes of Administration for Therapeutic Antibodies—state of the art. Antibodies (Basel). 2022;11(3):56. doi:10.3390/antib11030056.
   PubMedGoogle Scholar
• Ghosh I, Gutka H, Krause ME, Clemens R, Kashi RS. A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations. MAbs. 2023;15(1):2205540. doi:10.1080/19420862.2023.2205540.
   PubMed Web of Science ®Google Scholar
• Strickley RG, Lambert WJ. A review of formulations of commercially available antibodies. J Pharm Sci. 2021;110(7):2590–608 e2556. doi:10.1016/j.xphs.2021.03.017.
   PubMed Web of Science ®Google Scholar
• Deokar V, Sharma A, Mody R, Volety SM. Comparison of strategies in development and manufacturing of low viscosity, ultra-high concentration formulation for IgG1 antibody. J Pharm Sci. 2020;109:3579–89. doi:10.1016/j.xphs.2020.09.014.
   PubMed Web of Science ®Google Scholar
• Chari R, Jerath K, Badkar AV, Kalonia DS. Long- and short-range electrostatic interactions affect the rheology of highly concentrated antibody solutions. Pharm Res. 2009;26(12):2607–18. doi:10.1007/s11095-009-9975-2.
   PubMed Web of Science ®Google Scholar
• Tomar DS, Kumar S, Singh SK, Goswami S, Li L. Molecular basis of high viscosity in concentrated antibody solutions: strategies for high concentration drug product development. MAbs. 2016;8(2):216–28. doi:10.1080/19420862.2015.1128606.
   PubMed Web of Science ®Google Scholar
• Lilyestrom WG, Yadav S, Shire SJ, Scherer TM. Monoclonal antibody self-association, cluster formation, and rheology at high concentrations. J Phys Chem B. 2013;117(21):6373–84. doi:10.1021/jp4008152.
   PubMed Web of Science ®Google Scholar
• Liu J, Nguyen MD, Andya JD, Shire SJ. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci. 2005;94:1928–40. doi:10.1002/jps.20347.
   PubMed Web of Science ®Google Scholar
• Arora J, Hu Y, Esfandiary R, Sathish HA, Bishop SM, Joshi SB, Middaugh CR, Volkin DB, Weis DD. Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity. MAbs. 2016;8(8):1561–74. doi:10.1080/19420862.2016.1222342.
   PubMed Web of Science ®Google Scholar
• Kanai S, Liu J, Patapoff TW, Shire SJ. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab–Fab interaction that impacts solution viscosity. J Pharm Sci. 2008;97(10):4219–27. doi:10.1002/jps.21322.
   PubMed Web of Science ®Google Scholar
• Yadav S, Laue TM, Kalonia DS, Singh SN, Shire SJ. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions. Mol Pharm. 2012;9:791–802. doi:10.1021/mp200566k.
   PubMed Web of Science ®Google Scholar
• Bethea D, Wu SJ, Luo J, Hyun L, Lacy ER, Teplyakov A, Jacobs SA, O’Neil KT, Gilliland GL, Feng Y. Mechanisms of self-association of a human monoclonal antibody CNTO607. Protein Eng Des Sel. 2012;25(10):531–37. doi:10.1093/protein/gzs047.
   PubMed Web of Science ®Google Scholar
• Esfandiary R, Parupudi A, Casas-Finet J, Gadre D, Sathish H. Mechanism of reversible self-association of a monoclonal antibody: role of electrostatic and hydrophobic interactions. J Pharm Sci. 2015;104:577–86. doi:10.1002/jps.24237.
   PubMed Web of Science ®Google Scholar
• Geoghegan JC, Fleming R, Damschroder M, Bishop SM, Sathish HA, Esfandiary R. Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering. MAbs. 2016;8(5):941–50. doi:10.1080/19420862.2016.1171444.
   PubMed Web of Science ®Google Scholar
• Apgar JR, Tam ASP, Sorm R, Moesta S, King AC, Yang H, Kelleher K, Murphy D, D’Antona AM, Yan G. et al. Modeling and mitigation of high-concentration antibody viscosity through structure-based computer-aided protein design. PloS One. 2020;15(5):e0232713. doi:10.1371/journal.pone.0232713.
   PubMed Web of Science ®Google Scholar
• Chow CK, Allan BW, Chai Q, Atwell S, Lu J. Therapeutic antibody engineering to improve viscosity and phase separation guided by crystal structure. Mol Pharm. 2016;13:915–23. doi:10.1021/acs.molpharmaceut.5b00817.
   PubMed Web of Science ®Google Scholar
• Tilegenova C, Izadi S, Yin J, Huang CS, Wu J, Ellerman D, Hymowitz SG, Walters B, Salisbury C, Carter PJ. Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies. MAbs. 2020;12(1):1692764. doi:10.1080/19420862.2019.1692764.
   PubMed Web of Science ®Google Scholar
• Domnowski M, Lo Presti K, Binder J, Reindl J, Lehmann L, Kummer F, Wolber M, Satzger M, Dehling M, Jaehrling J. et al. Generation of mAb variants with less attractive self-interaction but preserved target binding by well-directed mutation. Mol Pharm. 2021;18:236–45. doi:10.1021/acs.molpharmaceut.0c00848.
   PubMedGoogle Scholar
• Shan L, Mody N, Sormani P, Rosenthal KL, Damschroder MM, Esfandiary R. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in silico tools. Mol Pharm. 2018;15:5697–710. doi:10.1021/acs.molpharmaceut.8b00867.
   PubMed Web of Science ®Google Scholar
• Wolf Perez AM, Lorenzen N, Vendruscolo M, Sormanni P. Assessment of therapeutic antibody developability by combinations of in vitro and in silico methods. Methods Mol Biol. 2022;2313:57–113. doi:10.1007/978-1-0716-1450-1_4.
   PubMedGoogle Scholar
• Cunningham BC, Wells JA. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Sci. 1989;244(4908):1081–85. doi:10.1126/science.2471267.
   PubMed Web of Science ®Google Scholar
• Cloutier TK, Sudrik C, Mody N, Sathish HA, Trout BL. Machine Learning Models of Antibody–excipient preferential interactions for use in computational formulation design. Mol Pharm. 2020;17(9):3589–99. doi:10.1021/acs.molpharmaceut.0c00629.
   PubMedGoogle Scholar
• Cloutier TK, Sudrik C, Mody N, Hasige SA, Trout BL. Molecular computations of preferential interactions of proline, arginine.HCl, and NaCl with IgG1 antibodies and their impact on aggregation and viscosity. MAbs. 2020;12(1):1816312. doi:10.1080/19420862.2020.1816312.
   PubMed Web of Science ®Google Scholar
• Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. 2007;372:774–97. doi:10.1016/j.jmb.2007.05.022.
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A. 2009;106:11937–42. doi:10.1073/pnas.0904191106.
   PubMed Web of Science ®Google Scholar
• Baker NA. Poisson-Boltzmann methods for biomolecular electrostatics. Methods Enzymol. 2004;383:94–118. doi:10.1016/S0076-6879(04)83005-2.
   PubMed Web of Science ®Google Scholar
• Morrison KL, Weiss GA. Combinatorial alanine-scanning. Curr Opin Chem Biol. 2001;5:302–07. doi:10.1016/s1367-5931(00)00206-4.
   PubMed Web of Science ®Google Scholar
• Sanner MF, Olson AJ, Spehner JC. Reduced surface: an efficient way to compute molecular surfaces. Biopolymers. 1996;38(3):305–20. doi:10.1002/(SICI)1097-0282(199603)38:3<305:AID-BIP4>3.0.CO;2-Y.
   PubMed Web of Science ®Google Scholar
• Johnson G, Wu TT. Kabat database and its applications: 30 years after the first variability plot. Nucleic Acids Res. 2000;28(1):214–18. doi:10.1093/nar/28.1.214.
   PubMed Web of Science ®Google Scholar
• Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. Bethesda, MD: NIH; 1991.
   Google Scholar
• Hötzel I, Theil F-P, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D. et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs. 2012;4:753–60. doi:10.4161/mabs.22189.
   PubMed Web of Science ®Google Scholar
• Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucl Acids Res. 2020;48(W1):W449–54. doi:10.1093/nar/gkaa379.
   PubMed Web of Science ®Google Scholar
• Prihoda D, Maamary J, Waight A, Juan V, Fayadat-Dilman L, Svozil D, Bitton DA. BioPhi: a platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning. MAbs. 2022;14(1):2020203. doi:10.1080/19420862.2021.2020203.
   PubMed Web of Science ®Google Scholar
• Raybould MIJ, Marks C, Krawczyk K, Taddese B, Nowak J, Lewis AP, Bujotzek A, Shi J, Deane CM. Five computational developability guidelines for therapeutic antibody profiling. Proc Natl Acad Sci U S A. 2019;116:4025–30. doi:10.1073/pnas.1810576116.
   PubMed Web of Science ®Google Scholar
• Kingsbury JS, Saini A, Auclair SM, Fu L, Lantz MM, Halloran KT, Calero-Rubio C, Schwenger W, Airiau CY, Zhang J. et al. A single molecular descriptor to predict solution behavior of therapeutic antibodies. Sci Adv. 2020;6(32):eabb0372. doi:10.1126/sciadv.abb0372.
   PubMed Web of Science ®Google Scholar
• Dingfelder F, Henriksen A, Wahlund PO, Arosio P, Lorenzen N. Measuring self-association of antibody lead candidates with dynamic light scattering. Methods Mol Biol. 2022;2313:241–58. doi:10.1007/978-1-0716-1450-1_14.
   PubMedGoogle Scholar
• Arosio P, Muller T, Rajah L, Yates EV, Aprile FA, Zhang Y, Cohen SI, White DA, Herling TW, De Genst EJ. et al. Microfluidic diffusion analysis of the sizes and interactions of proteins under native solution conditions. Acs Nano. 2016;10(1):333–41. doi:10.1021/acsnano.5b04713.
   PubMed Web of Science ®Google Scholar
• Kopp MRG, Arosio P. Microfluidic approaches for the characterization of therapeutic proteins. J Pharm Sci. 2018;107:1228–36. doi:10.1016/j.xphs.2018.01.001.
   PubMed Web of Science ®Google Scholar
• Starr CG, Makowski EK, Wu L, Berg B, Kingsbury JS, Gokarn YR, Tessier PM. Ultradilute measurements of self-association for the identification of antibodies with favorable high-concentration solution properties. Mol Pharm. 2021;18:2744–53. doi:10.1021/acs.molpharmaceut.1c00280.
   PubMedGoogle Scholar
• Sule SV, Dickinson CD, Lu J, Chow CK, Tessier PM. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. Mol Pharm. 2013;10:1322–31. doi:10.1021/mp300524x.
   PubMed Web of Science ®Google Scholar
• Phan S, Walmer A, Shaw EW, Chai Q. High-throughput profiling of antibody self-association in multiple formulation conditions by PEG stabilized self-interaction nanoparticle spectroscopy. MAbs. 2022;14(1):2094750. doi:10.1080/19420862.2022.2094750.
   PubMed Web of Science ®Google Scholar
• Leem J, Dunbar J, Georges G, Shi J, Deane CM. ABodyBuilder: automated antibody structure prediction with data–driven accuracy estimation. MAbs. 2016;8(7):1259–68. doi:10.1080/19420862.2016.1205773.
   PubMed Web of Science ®Google Scholar
• Gupta P, Makowski EK, Kumar S, Zhang Y, Scheer JM, Tessier PM. Antibodies with weakly basic isoelectric points minimize trade-offs between formulation and physiological colloidal properties. Mol Pharm. 2022;19:775–87. doi:10.1021/acs.molpharmaceut.1c00373.
   PubMedGoogle Scholar
• Kuroda D, Tsumoto K. Engineering stability, viscosity, and immunogenicity of antibodies by computational design. J Pharm Sci. 2020;109:1631–51. doi:10.1016/j.xphs.2020.01.011.
   PubMed Web of Science ®Google Scholar
• Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. The covalent structure of an entire γg immunoglobulin molecule. Proc Natl Acad Sci U S A. 1969;63(1):78–85. doi:10.1073/pnas.63.1.78.
   PubMed Web of Science ®Google Scholar
• Pullmann P, Ulpinnis C, Marillonnet S, Gruetzner R, Neumann S, Weissenborn MJ. Golden mutagenesis: an efficient multi-site-saturation mutagenesis approach by golden Gate cloning with automated primer design. Sci Rep. 2019;9(1):10932. doi:10.1038/s41598-019-47376-1.
   PubMedGoogle Scholar
• Bos AB, Luan P, Duque JN, Reilly D, Harms PD, Wong AW. Optimization and automation of an end-to-end high throughput microscale transient protein production process. Biotechnol Bioeng. 2015;112:1832–42. doi:10.1002/bit.25601.
   PubMed Web of Science ®Google Scholar
• Koth CM, Murray JM, Mukund S, Madjidi A, Minn A, Clarke HJ, Wong T, Chiang V, Luis E, Estevez A. et al. Molecular basis for negative regulation of the glucagon receptor. Proc Natl Acad Sci U S A. 2012;109:14393–98. doi:10.1073/pnas.1206734109.
   PubMed Web of Science ®Google Scholar
• Kabsch W. Xds. Acta Crystallogr D Biol Crystallogr. 2010;66(2):125–32. doi:10.1107/S0907444909047337.
   PubMedGoogle Scholar
• Evans PR, Murshudov GN. How good are my data and what is the resolution? Acta Crystallogr D Biol Crystallogr. 2013;69(7):1204–14. doi:10.1107/S0907444913000061.
   PubMedGoogle Scholar
• Karplus PA, Diederichs K. Linking crystallographic model and data quality. Sci. 2012;336(6084):1030–33. doi:10.1126/science.1218231.
   PubMed Web of Science ®Google Scholar
• Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of coot. Acta Crystallogr D Biol Crystallogr. 2010;66(4):486–501. doi:10.1107/S0907444910007493.
   PubMedGoogle Scholar
• Liebschner D, Afonine PV, Baker ML, Bunkoczi G, Chen VB, Croll TI, Hintze B, Hung LW, Jain S, McCoy AJ. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D Struct Biol. 2019;75(10):861–77. doi:10.1107/S2059798319011471.
   PubMedGoogle Scholar
• Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, Mustyakimov M, Terwilliger TC, Urzhumtsev A, Zwart PH, Adams PD. Towards automated crystallographic structure refinement with phenix.Refine. Acta Crystallogr D Biol Crystallogr. 2012;68(4):352–67. doi:10.1107/S0907444912001308.
   PubMedGoogle Scholar
• Molecular Operating Environment (MOE). 2022. 02 Chemical Computing Group ULC, 910-1010 Sherbrooke St. W., Montreal, QC H3A 2R7, Canada, 2023.
   Google Scholar
• Dolinsky TJ, Nielsen JE, McCammon JA, Baker NA. PDB2PQR: an automated pipeline for the setup of poisson-boltzmann electrostatics calculations. Nucleic Acids Res. 2004;32(Web Server):W665–667. doi:10.1093/nar/gkh381.
   PubMedGoogle Scholar
• Sondergaard CR, Olsson MH, Rostkowski M, Jensen JH. Improved treatment of ligands and coupling effects in empirical calculation and rationalization of pKa values. J Chem Theory Comput. 2011;7:2284–95. doi:10.1021/ct200133y.
   PubMed Web of Science ®Google Scholar
• Olsson MH, Sondergaard CR, Rostkowski M, Jensen JH. PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theory Comput. 2011;7:525–37. doi:10.1021/ct100578z.
   PubMed Web of Science ®Google Scholar
• Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci. 2012;101:102–15. doi:10.1002/jps.22758.
   PubMed Web of Science ®Google Scholar
• Case DA, Ben-Shalom IY, Brozell SR, Cerutti DS, Cheatham I, Cruzeiro VWD, Darden TA, Duke RE, Ghoreishi D, Giambasu G. et al. AMBER 2019. San Francisco: University of California; 2019
   Google Scholar
• Salomon-Ferrer R, Case DA, Walker RC. An overview of the amber biomolecular simulation package. Wiley Interdiscip Rev Comput Mol Sci. 2013;3:198–210. doi:10.1002/wcms.1121.
   Web of Science ®Google Scholar
• Salomon-Ferrer R, Gotz AW, Poole D, Le Grand S, Walker RC. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh ewald. J Chem Theory Comput. 2013;9:3878–88. doi:10.1021/ct400314y.
   PubMed Web of Science ®Google Scholar
• Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11(8):3696–713. doi:10.1021/acs.jctc.5b00255.
   PubMed Web of Science ®Google Scholar
• Jorgensen WL, Chandreasekhar J, Madura JD, I RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79(2):926–35. doi:10.1063/1.445869.
   Web of Science ®Google Scholar
• Rasouli M. Basic concepts and practical equations on osmolality: biochemical approach. Clin Biochem. 2016;49:936–41. doi:10.1016/j.clinbiochem.2016.06.001.
   PubMed Web of Science ®Google Scholar
• Bjellqvist B, Hughes GJ, Pasquali C, Paquet N, Ravier F, Sanchez JC, Frutiger S, Hochstrasser D. The focusing positions of polypeptides in immobilized pH gradients can be predicted from their amino acid sequences. Electrophoresis. 1993;14(1):1023–31. doi:10.1002/elps.11501401163.
   PubMedGoogle Scholar
• Bjellqvist B, Basse B, Olsen E, Celis JE. Reference points for comparisons of two-dimensional maps of proteins from different human cell types defined in a pH scale where isoelectric points correlate with polypeptide compositions. Electrophoresis. 1994;15(1):529–39. doi:10.1002/elps.1150150171.
   PubMed Web of Science ®Google Scholar
• Raybould MIJ, Deane CM. The therapeutic antibody profiler for computational developability assessment. Methods Mol Biol. 2022;2313:115–25. doi:10.1007/978-1-0716-1450-1_5.
   PubMedGoogle Scholar
• Olsen TH, Boyles F, Deane CM. Observed antibody space: a diverse database of cleaned, annotated, and translated unpaired and paired antibody sequences. Protein Sci. 2022;31:141–46. doi:10.1002/pro.4205.
   PubMed Web of Science ®Google Scholar
• Marrama D, Chronister WD, Westernberg L, Vita R, Kosaloglu-Yalcin Z, Sette A, Nielsen M, Greenbaum JA, Peters B. Pepmatch: a tool to identify short peptide sequence matches in large sets of proteins. BMC Bioinform. 2023;24(1):485. doi:10.1186/s12859-023-05606-4.
   PubMed Web of Science ®Google Scholar